Proactive Investors
29 May 2026, 20:31 UTC · 2h ago
BioVie: Long COVID trial fully enrolled – ICYMI
Source · https://www.proactiveinvestors.com/companies/news/1093159
Read source
Search tags
Proactive Investors
29 May 2026, 20:31 UTC · 2h ago
Source · https://www.proactiveinvestors.com/companies/news/1093159
Read sourceSearch tags
Story key points
4 claims · impact-rated
BioVie Inc. expects to release top-line results from its Phase 2 long COVID trial for bezisterim by September or October. — Clinical trial data is the primary catalyst for biotech valuations, with the potential for significant price volatility upon release.
+0.60BioVie has achieved full enrollment of over 200 patients for its Phase 2 long COVID study, with participants from institutions such as Yale and Mayo Clinic. — Completion of enrollment removes a key operational risk and moves the company closer to the data readout phase.
+0.30The company has received a $13 million grant to support the exploration of bezisterim in long COVID patients. — Non-dilutive funding reduces cash burn and provides a signal of institutional validation for the drug's potential.
+0.20Continue reading
6 related stories
CEO Cuong Do claims that capturing a fraction of the 3 million severely impacted long COVID patients could lead to annual sales exceeding $10 billion. — While high, this is a speculative projection of a total addressable market (TAM) rather than a realized financial event.
+0.10Ticker attribution
Model heads
The company achieved full enrollment in its Phase 2 long COVID trial and secured a $13 million grant.
No ticker relationship head found.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Newsfile Corp
7h ago
